

birac

i3

Ignite • Innovate • Incubate



BIRAC's Role in Fostering the Biotech Innovation Ecosystem in India



Biotechnology Industry Research Assistance Council
(A Government of India Enterprise)



July-September 2022

No. 2 Vol. 9



birac

EDITORIAL COMMITTEE

Dr. Shirshendu Mukherjee

Mission Director
Grand Challenges India

Ms. Ginny Bansal

Consultant (Comm.)
Grand Challenges India

Ms. Himanshi Sharma

Consultant (Comm.)
National Biopharma Mission

DESIGN AND PRODUCTION

Chiranjn Adverting, E-170, East of Kailash, New Delhi -110065

CONTENT

IN THIS ISSUE

Leader's Message	02
Chief Editor's Take	03
BIRAC Feature	04
BIRAC Reports	07
Amrit Grand Challenge – JanCARE	
BIRAC Workshop on Bio-entrepreneurship and Intellectual Property & Technology Management	
IP & Technology Management Law Clinic Connect	
Session on “Investor's Perspective on Biotech Startup Pitches”	
Release of India Bioeconomy Report 2022	
HR & Admin Activities	13
'Har Ghar Tiranga' Campaign	
Training on Work Life Balance	
Hindi Pakhwada 2022-23	
Partnerships	18
Grand Challenges India call on Diagnostics for Neglected Tropical Disease (NTD) – Lymphatic Filariasis (LF)	
Scientific completion of India's First Indigenous HPV vaccine	
National Programmes	21
Data Cleaning and Geographical Information System (GIS) sensitization sessions for DRIVEN-Demographic Health Surveillance Sites	
Society for Health Allied Research & Education (SHARE) India Mentoring and Monitoring visit	
Call Launches	23
Indo US Clinical Research Ethics Fellowship Under the Aegis of Indo-US Vaccine Action Programme (VAP)	



From the Leaders Desk



(Dr Rajesh S Gokhale)
Secretary DBT
& Chairperson BIRAC

The biotechnology sector has the potential to have a cascading multiplier effect on the overall economic growth of the country. This sunrise sector enables technology-led solutions for Healthcare, Industrial manufacturing, Agriculture, Environment, and Clean Energy.

India is among the top 3 in South Asia and the top 12 destinations for biotechnology in the world, with approximately a 3% share in the global Biotechnology industry. The Global Innovation Index rank for India has improved from 81st in 2015 to 40th in 2022 in just 7 years. The startup ecosystem is also poised to scale to 10,000 biotech startups propelling the innovation and knowledge translation into products that are Made in India – for India and for the world.

We at BIRAC believe that accelerating economic growth and sustaining it, is a critical responsibility to create a new Atma Nirbhar Bharat. From large manufacturers to young startups, the innovation ecosystem in the country has come together to provide solutions for India and the world. The startups in the biotech ecosystem represent the knowledge that is essential for the growth and development of the ecosystem and addresses unmet societal needs.

The number of Biotech Startups in the country has increased from 50 to over 5,300 in the last 10 years, because of the growing enabling ecosystem and prioritization by Government of India. Biotech Startups founded by strong talent pool is expected to further increase 2 times to 10,000+ by 2025. This can happen only, when we harness potential of India's diverse ecosystem from across all geographies. BIRAC/ DBT has established a strong network of 74 specialized bioincubation centres across the country. I am pleased to note that it includes 7 bio incubators in the north east region which is an emerging cluster.

This year is particularly noteworthy as it coincides with the Azadi Ka Amrit Mahotsav, a celebration of our nation's 75 years of independence. We are confident that we would keep contributing to energize the innovation ecosystem.

Chief Editor's Take



Dr. Alka Sharma
Senior Advisor, DBT &
Managing Director-BIRAC

The Indian Biotechnology sector has entered a new phase of growth where the world acknowledges the enormous potential this sector holds to touch and transform lives. The biotechnology sector has been recognized as the sunshine sector for India that has a cascading multiplier effect on the Indian Economy.

There is a great potential for the Indian Biotech Sector to become a global hub for manufacturing of biologics; innovating globally competitive, novel, affordable vaccines, biosimilars and advanced immuno-therapeutics that are accessible to all. India's BioEconomy has crossed \$80 billion mark in 2021. The nation has set an ambitious target for the BioEconomy to touch the \$150 billion threshold by 2025.

The Department of Biotechnology (DBT) setup Biotechnology Industry Research Assistance Council (BIRAC), to act as an interface agency to strengthen and empower emerging biotech enterprises. In the relatively short 10 years of BIRAC's existence, the impact on the Biotech Innovation Landscape is creditably immense. Support from BIRAC in nurturing the talent pool, providing opportunities to startups to Seed, Succeed and Scale is evident.

I am glad to notice that the startups have received not only funding support but access to mentors and expertise for regulatory, go-to-market strategy development, fundraising and commercialization which has also been facilitated by BIRAC. Since its inception, BIRAC has taken up a multitude of activities, from financing high-risk research to supporting nascent ideas; creating bio-incubation centres for shared infrastructure and capacity building to policy advocacy for empowering the biotech ecosystem in India.



From large manufacturers to young start-ups, the innovation ecosystem in the country has come together. Today, India is self-sufficient in most of the products required to manage the pandemic and we need to keep this momentum. The biotech innovation ecosystem is expected to contribute more affordable, accessible & globally competitive solutions to address unmet needs of the society.

I am confident that BIRAC will continue to showcase India's potential both within the country and to the world in order to catapult India's biotech sector on the global map. We must integrate to harness the full potential of Make In India and Startup India missions to be ready for the Amrit-Kaal.

BIRAC's Role in Fostering the Biotech Innovation Ecosystem in India

Biotechnology is currently recognized as the sunrise sector- a key driver for contributing to India's USD 5 Trillion economy target by 2025. India is among the Top 12 destinations for biotechnology worldwide and 3rd largest destination for biotechnology in the Asia Pacific. In 2022, India's Biotechnology industry has crossed US\$80.12 Billion, growing 14% from the previous year. It is poised to grow exponentially over the next decade. The Indian Bioeconomy has witnessed a manyfold increase in valuation in the past ten years, with COVID-19 giving the industry a much-needed push. The pandemic brought a new sense of urgency to innovation efforts. The COVID pandemic has witnessed the critical impact of made-in-India novel vaccines, diagnostics, healthcare delivery, and management solutions endorsing India's growing strength towards Aatmanirbhar Bharat.

The Hon'ble Prime Minister Shri Narendra Modi at India's first Biotech Startup Expo said, "India's bio-economy has grown eight times in the last eight



years from \$10 billion to \$80 billion and that India is not too far from reaching the league of top 10 countries in biotech's global ecosystem".


BIRAC has played a huge role in the new leap that India has taken in nurturing and reinventing the innovation ecosystem. BIRAC has made an important contribution to the unprecedented expansion of research and innovation in India in the past few years. At a time when India is celebrating the Azadi ka Amrit Mahotsav and is setting new goals for the next 25 years, the role of the biotech sector is very important in giving a new impetus to the country's development. In the

last 10 years, BIRAC has supported innovations in varied areas of biotechnology and has worked aggressively on building new pathways for an entrepreneurial journey through early-stage funding, incubation, product commercialization support, and equity funding.

The various schemes and programs of BIRAC have been carefully curated to cater to the entire product development cycle vis-a-vis ideation, proof of concept, validation, and commercialization.

The biotech sector has also benefited greatly from the steps that have been taken in the last few years under the Atal Innovation Mission, Startup India, Make in India, and AtmaNirbhar Bharat campaign. The number of people investing in biotech start-ups has grown by nine times since the launch of Start-Up India. The number of biotech incubators and total funding has also increased by almost seven times. In 2014, there were only six bio-incubators in our country, today it has increased to 75.

The last few years have seen a surge in the growing biotech innovation ecosystem. Biotechnology today holds enormous potential for impacting the economic growth of the country. Globally there has been a major push towards encouraging the growth of the Start-up and entrepreneurial ecosystem to contribute to the biotech industry. BIRAC with its key strategies to foster innovation and entrepreneurship has emerged as a key enabler for entrepreneurs looking to make an impact through innovative solutions. BIRAC over the years has worked as a core development agency with a focus on the entire product development chain. The emphasis is not only on providing funding but also handholding the entrepreneurs to grow and take their ideas forward to the product development stage i.e moving from lab 2 Market. The enabling ecosystem allows young innovators to take the plunge into



high-risk and high-reward innovation research for meeting Societal needs. BIRAC has created a vibrant start-up ecosystem, facilitated a very strong industry-academia linkage, and connected the ecosystem both nationally and internationally through enabling policies. With over 1000 startups and entrepreneurs and more than 500 small companies and industries being a part of this network, it is

encouraging to see that today there are more than 130 products and technologies that have been successfully developed. Our 40 bio incubators play a very important role in the growth of the ecosystem, providing the start-ups the required technical, business, financial, and regulatory mentorship. BIRAC has supported innovations that address the complex societal challenges in the supported innovations which address the complex societal challenges in health care, agriculture, environment, and energy and are focused on improving the lives of millions in our country. BIRAC's main thrust is on human resource and capacity building, Access to resources for

start-ups, industry-academia partnerships, and access to investor networks and markets.

All components of the ecosystem from mentorship to capacity building to financing and product commercialization are being supported by BIRAC. This has now resulted not only in an excellent pipeline of startups but also in several successful enterprises which have made an impact both in the domestic and global arena. 'Many startups have been able to attract investments which are crucial and critical for the sustainability and scalability of the enterprise.

The Indian biotechnology sector has entered a new phase of growth where the world acknowledges the enormous potential this sector holds to touch and transform lives. Over the last 10 years, BIRAC has taken up a multitude of activities, from financing high-risk research to supporting nascent ideas; creating bioincubation centres for shared infrastructure and capacity building to policy advocacy for empowering the biotech ecosystem in India.

BIRAC recently launched the "India Bioeconomy Report 2022, for more details please read https://birac.nic.in/webcontent/1658318307_India_Bioeconomy_Report_2022.pdf.

Amrit Grand Challenge – JanCARE

The evaluation process for Amrit Grand Challenge – The two-day online interview for stage 2 selection process was held on 3rd and 4th August 2022 in which 10 applicants were selected for the stage 3 evaluation process. The stage 3 evaluation process under the AGC JanCare challenge was held on 5th August 2022 in Hyderabad.



The manager of iHub Anubhuti-IIITD Foundation, Mr. Abhishek Bhattacharya, partner-JanCare has attended the evaluation process in person and was the part of selection committee. The official results of the final evaluation is yet to be announced by BIRAC.

BIRAC in partnership with iHub Anubhuti – IIITD Foundation and other partners will ensure that great ideas seamlessly reach the last mile. The latest collaboration between BIRAC and iHUB in digital health initiative i.e., जनCARE Challenge is a testament to the significant impact that can be brought together.



BIRAC Workshop on Bio-entrepreneurship and Intellectual Property & Technology Management


BIRAC organized a one-day workshop in association with Pondicherry University on “Bio-entrepreneurship and Intellectual Property & Technology Management” on 19th September, 2022. Workshop was attended by around 150 participants which had the representation from PhDs, Post docs, aspiring entrepreneurs, start-ups and Faculties from Pondicherry University as well as from other institutions. The focus of the workshop was on role of BIRAC for creating and nurturing the entrepreneurship in Biotech sector, key elements required for effective writing of grant proposal and nuances of Intellectual Property Rights and Technology Commercialization.



IP & Technology Management Law Clinic Connect

BIRAC conducted two (2) sessions of “IP & Technology Management Law Clinic Connect” for the Startups, Institutes, and Entrepreneurs to advise and mentor on Patentability Criteria, Patentable subject matter, strategy for foreign patent filing, Technology Transfer and Commercialization Process, creation of spin-off as well as on equity allocation. Sessions were well attended by 10 Start-ups and entrepreneurs as per their allotted slots.

The Clinic operates on Second Friday of every Month through Video-conferencing from 4 pm to 6 pm.



Session on “Investor's Perspective on Biotech Startup Pitches”

Biotechnology Industry Research Assistance Council (BIRAC) in association with Startup India and Indian Venture and Alternative Capital Association (IVCA) organised a virtual session on “Investor’s Perspective on Biotech Startup Pitches”. It was held on 6th September 2022 from 3.30pm to 5.00pm.

During the session **Ms. Palak Bhatia**, Assistant Vice President - Startup India highlighted about the Indian Startup Ecosystem, **Dr. Manish Diwan**, Head - Strategic Partnership & Entrepreneurship Development, BIRAC gave a brief introduction of Biotech Startups potential to the Investor network and **Mr. Saurabh Singh**, Growth Investor, Trifecta Capital reviewed the investment trends from Indian healthcare/Biotech/Pharma Ecosystem.

The session also included a panel discussion on “What Investors look for in a healthcare/Biotech/Pharma Ecosystem Startups”. The Panelist were **Mr. Saurabh Singh**, Growth Investor, Trifecta Capital, **Mr. Arpit Agarwal**, Director, Blume Ventures (Moderator) **Dr Pinak Shrikhande**, Director, Healthquad, **Dr Mansi Aggarwal**, Partner, Alkemi Venture Partner. The panelists shared their experiences and insights to help entrepreneurs identify the key challenges and opportunities in terms of pitch decks.

Mr. Arpit Agarwal moderated the panel discussion. The session later was opened to the Startups for the questions and answers. The proceedings are available at <https://youtu.be/85HQHMgpa>.

Biotech Ecosystem Growth

Nurturing Innovation from Ideation to Commercialization

Biotech sector: Investment Heavy | High Risk | Long Gestation | Low Success | High Reward

Outcome	2012	Multiplier	2022
Biotech Startups	50	100x	5300+
Incubators	6	12x	74
Number of Products	10	70x	700
Fund Raised (INR)	10 Cr	400x	4200 Cr+
Jobs Created	250	100x	25000
IP filed	~50	20x	1100+
Bio-Economy (\$ USD)	<10 Bn	8x	80.1 Bn

Healthcare, Industrial Biotech, Agriculture and allied areas, Waste Management, Sanitation and Clean Energy

Release of India Bioeconomy Report 2022

The Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India along with its Public Sector Undertaking, Biotechnology Industry Research Assistance Council (BIRAC) organized the release event of “India Bioeconomy Report 2022” on 19th July 2022 at CSIR, New Delhi.

Hon'ble Minister Dr Jitendra Singh, Union Minister of State (Independent Charge) Science & Technology; Minister of State (Independent Charge) Earth Sciences; MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space, launched the “India Bioeconomy Report 2022” at the event.



The Hon'ble Minister at the release event opined that the Bioeconomy of the country has reached 80.1 billion USD in 2021 recording 14.1% growth of over \$70.2 billion in 2020. A two-fold increase in biofuel production, and self-reliance for COVID vaccines and diagnostics in 2021 has showed that there is a potential for India to become global bio manufacturing hub for biologics including vaccines, bio similar, diagnostics and other therapeutics. He lauded the efforts of BIRAC and said that the Biotech Startups in the country have increased from 50 to over 5,300 in the last 10 years, because of the growing enabling ecosystem and prioritization by the Government of India. Hon'ble Prime Minister Narendra Modi Ji's presence in the 1st National Biotech Startup Expo 2022 which was held on June 9-10, is a testimony of the growth potential in the biotech sector and the innovation talent pool of our Startup ecosystem.

The Hon'ble Minister also applauded DBT and BIRAC efforts in establishing a strong network of 74 specialized bioincubation centres in 21 states/ UTs which also includes 7 bioincubators in the North East region.



Indian Bioeconomy Report is an annual report that is published through the Make-in-India cell for Biotechnology at BIRAC with the help of ABLE (Association of Biotechnology Led Enterprises) which is available for official reference at national and international levels. The report acts as the guiding force for hosting national policies, regulations, and directives set out to reach an ambitious target of a \$150 billion Bioeconomy by 2025.

The event also witnessed the launch of a special call inviting the talent pool of the North East Region (NER) under Biotech Ignition Grant (BIG) – the flagship scheme of BIRAC. Hon'ble Minister's emphasis on the potential of NER which is aimed at nurturing a pipeline of biotech entrepreneurs and startups in the region.

The launch of 'Special BIG-NER' call to identify and support 25 Entrepreneurs and Startups includes:

- Biotech Ignition Grant of Upto INR 50 lakhs/ each to 25 entrepreneurs and startups
- Handholding, mentoring and access to BioNEST Incubation centres
- Skill development, extended networking and connect to the BIRAC's nurtured ecosystem.

The call is aimed at encouraging trained talent of NER origin for homecoming and drawing the attention of industry, and investor networks to the region.



Dr Rajesh S Gokhale, Secretary DBT and Chairperson BIRAC added “The release of Bioeconomy 2022 report could not be more apt, as it provides an interim progress report of our journey of AtmaNirbhar Bharat”. The event was attended by Dr Alka Sharma, Managing Director, BIRAC, industry representatives and DBT - BIRAC officials.

'Har Ghar Tiranga' Campaign

Government of India has approved the programme of 'Har Ghar Tiranga' under the aegis of the Azadi Ka Amrit Mahotsav (AKAM). The central theme of the programme was to inspire every Indian to hoist the National Flag at their home and invoke the feeling of patriotism in the hearts of the citizen and promote awareness about our National Flag.

Biotechnology Industry Research Assistance Council (BIRAC) in its extended efforts to celebrate "Azadi Ka Amrit Mahotsav" also initiated "Har Ghar Tiranga" Campaign with an aim to invoke the feeling of patriotism in the hearts of the citizen and promote awareness about our national flag.

To mark this momentous occasion, National Flags were made available to BIRAC officials and were encouraged to hoist/display the Indian National Flag from 13th to 15th August 2022. Also, they were requested to pin in the Flag and upload Selfie with Flag on the "Har Ghar Tiranga" Website.




Team BIRAC celebrated Har Ghar Tiranga – Azadi Ka Amrit Mahotsav

BIRAC also disseminated information related to "Har Ghar Tiranga" Campaign on BIRAC website and Social Media Platforms in order to generate enthusiasm and elicit peoples' involvement on mass scale. Few glimpses are given below:



To promote and propagate the "Har Ghar Tiranga" Campaign, Slogan writing, Essay writing and Poster making competitions were also organized. All employees participated with great enthusiasm in this event.



Training on Work Life Balance



In order to help employees to focus on relevant life and work matters, fulfill their personal and professional goals, training on Work-Life balance has been organised for BIRAC Officials on 03rd September 2022.

The training helped employees learn what work-life balance is and its advantages. Also, it helped officials reflect on obstacles to achieve balance and discover ways of overcoming them and create a sustainable equilibrium between the various elements of their life.

Few glimpses are given below:



Hindi Pakhwada 2022-23

Hindi Diwas is celebrated on 14 September with great pride and vigour as Hindi was adopted as the Official Language of our nation, India on September 14, 1949.

This year Biotechnology Industry Research Assistance Council observed Hindi Pakhwada from 14th September 2022 to 29th September 2022.

To promote and propagate the use of our national language, the following competitions/activities were organized during the Hindi Pakhwada:

1. Essay Writing - Individual Competition (Individual)
2. Administrative Terminology and Phrases Translation Competition (Departmental)
3. Official Language Hindi General Knowledge Quiz Competition (Departmental)
4. Hindi Workshop, by Consultant-Hindi.





Grand Challenges India call on Diagnostics for Neglected Tropical Disease (NTD) – Lymphatic Filariasis (LF)

Aligned with Government of India's accelerated plan to eliminate NTD's like Kala-Azar and LF, Grand Challenges India (GCI) has launched an open call on "Diagnostics for Neglected Tropical Disease (NTD) – Lymphatic Filariasis (LF)". It was proposed that program will make an effort to support diagnostics development in alignment with the World Health Organization (WHO) Diagnostic Technical Advisory Group-developed Target Product Profiles and are intended for field use in the National LF Elimination Programme, primarily in India and globally. The call was launched on the GCI-BIRAC website on June 7, 2022, for a 60-day period. As the RFP was India-led; the proposals were solicited from Indian academicians, research institutions, companies, society, trusts and foundations to develop/validate novel diagnostics for LF.


During the course of these 60 days, GCI team carried out the extensive call outreach activities. This entailed publicizing the call in all major newspapers (all India Editions). The GCI-BIRAC and applicable stakeholders' and partners databases was used to do the email blasts at regular intervals for call outreach. The BIRAC's Facebook, Twitter, and LinkedIn account was used to promote the call. Additionally, call was also promoted through booths at major GCI and BIRAC events. The GCI-BIRAC team conducted the webinar through virtual platform for promoting the call and the YouTube link for the same was disseminated.

The deadline for proposals submission under the call was 5th August 2022 till 05:00 PM. The program received 43 submissions of applications, under this call. The proposals received under the call underwent initial eligibility triage for completeness and mandate responsiveness by GCI along with stakeholders' team. 10 proposals were found out of the scope from the calls mandate, were marked ineligible. The 33 eligible proposals received under the call are being considered for review for expert assessment by Technical Advisory Group (TAG) constituted for the program.

The TAG comprising of subject matter specialist will evaluate the proposals received under the call and will recommend the most promising innovations for funding support. The TAG will also review and mentor the supported projects during the course of the program.

The TAG meeting for the initiative is scheduled for 11th, 12th and 13th October 2022 respectively. As applicable, the TAG recommended proposals will be further processed for Financial and Technical Due Diligence by GCI-BIRAC for funding support.


Scientific completion of India's First Indigenous HPV vaccine



The Department of Biotechnology (DBT) announced the scientific completion of India's first indigenously developed quadrivalent Human Papillomavirus (qHPV) vaccine (types 6,11,16 and 18), for the prevention of Cervical Cancer and Genital Warts on September 1st 2022 at India International Centre, New Delhi. The HPV vaccine has been developed by the Serum Institute of India Pvt Ltd. and will be launched soon. The vaccine received marketing authorization approval from the Drug Controller General of India (DCGI) on 12th July 2022. The development of the vaccine has been supported by the DBT through Grand Challenges India, implemented by the Biotechnology Industry Research Assistance Council (BIRAC).

This would be India's first indigenously developed quadrivalent HPV types (6,11,16 and 18) vaccine for cervical cancer and genital warts prevention. The vaccine will be administered as a two-dose for 9-14 years and as a three-dose schedule for 15-26 years. Indian vaccine is expected to be available at an affordable cost.

Union Minister of State (Independent Charge) Science & Technology; Minister of State (Independent Charge) Earth Sciences; MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space, Dr Jitendra Singh lauded the efforts of DBT in developing India's first indigenous vaccine for HPV. This vaccine will support India in reducing preventable cervical cancer deaths and protect our women and girls. He congratulated DBT and Serum Institute on this milestone achievement.



Dr Rajesh S Gokhale, Secretary, DBT and Chairperson, BIRAC, added that the Department has supported and enabled India's vaccine research and development capabilities.

Mr Adar Poonawalla, CEO, Serum Institute of India was also present at the occasion. He asserted that the scientific completion of the qHPV vaccine is a moment of pride for us, and India, at large. He thanked DBT and BIRAC for supporting in achieving this significant milestone.



Celebrity Manisha Koirala participated in the event virtually and shared about her experience fighting cancer and provided her wisdom and advice to the people on taking all steps possible to prevent this difficult disease.

Panel discussion aims to investigate the most recent advancements, innovations, and prospects in HPV vaccine research and development as well as current barriers impeding vaccination availability and distribution in developing nations. Further, the panel will also shed light on tailored strategies to spearhead vaccine advocacy and promote wider coverage. Dr Alka Sharma, Advisor, DBT and MD, BIRAC moderated the panel discussion. Dr. Neerja Bhatla, Prof. Gynaecology and Obstetrics, AIIMS, New Delhi,



Dr. Umesh Shaligram, Executive Director, Serum Institute of India, Pune, Dr. Guruprasad R. Medigeshi, Asst. Prof., THSTI, Faridabad, and Dr. Devasena Anantharaman, Scientist, RGCB, Thiruvananthapuram also took part in the panel discussion.



Data Cleaning and Geographical Information System (GIS) sensitization sessions for DRIVEN-Demographic Health Surveillance Sites

The Data Cleaning and GIS-related sensitization session was conducted on-site for the DRIVEN DHS sites in the month of August and September in collaboration with INCLEN and CDSA, sponsored by BIRAC-NBM. Five Clinical Trial Network community sites participated in these trainings with an objective (a) to understand the Data discrepancies reported on SOMAARTH electronic data collection platform



deployed for the DRIVEN study, (b) steps involved in data cleaning process, (c) any open action items related to Investigators' Site Master File/ logs/ forms/ Standard Operating Procedures., and (d) GIS-related discussion.

Participating DRIVEN Sites

Andhra Medical College, Vishakhapatnam

Maulana Azad Medical College, New Delhi

Centre for Health Research and Development, Society for Applied Studies, New Delhi

ICMR-RMRC, Tigris, Bhubaneswar

Puducherry Institute of Medical Sciences, Puducherry



Focused on harmonizing the census as well as demographic health data within the DBT's Resource of Indian Vaccine Epidemiology (DRIVEN) Network, managing the data of the cohort of > 300,000 population across India.

Society for Health Allied Research & Education (SHARE) India Mentoring and Monitoring visit

Under DBT's Resource of Indian Vaccine Epidemiology (DRIVEN) Network, clinical trial network community sites (05) are conducting the seroepidemiological study on SARS-CoV-2, Dengue, and Chikungunya across the country with the support from National Biopharma Mission.

The project activities are being monitored by Clinical Development Services Agency (CDSA) ensuring good clinical/laboratory and documentation practices. The Pan-India network data is being managed by SOMAARTH (electronic data collection tool). In July 2022, SHARE India located at Medchal near Hyderabad (TS, India) was visited by NBM and CDSA team.

Through regular meetings (online and onsite) efforts are put to ensure compliance to good clinical practices. All the network partners are mentored and monitored regularly to ensure smooth implementation of the study being conducted in different parts of the country.



Indo US Clinical Research Ethics Fellowship Under the Aegis of Indo-US Vaccine Action Programme (VAP)

Indo-US Clinical Research Ethics Fellowship programme RFP published on 1st July 2022 to support motivated individuals with strong scientific background with interest in the field of bioethics. The RFP for fellowship aims towards building a critical mass of trained scholars who will contribute actively to the international literature on clinical research ethics, and who will be able to advice clinical researchers, administrators and policy makers in India on emerging issues.

The program will support research projects in the field of clinical research ethics including, but not limited to, ethical aspects of:


- Ethical aspects of vaccine research and clinical trial
- Research subject recruitment in clinical research
- Informed consent taken during the clinical research
- Research with stored biological specimens
- Return of unanticipated research results
- Research on novel technologies such as stem cells, CAR-T treatment, and gene therapy

Total Fellowship for each selected fellow candidate [in lakhs (INR)]

a) Fellowship with permanent position 6.00 or

b) Fellowship without permanent position 30.60

In addition to the fellowship, a research grant, not exceeding Rs. 40 Lakhs for a period of three years for each selected fellow candidate.



बायोटेक्नोलॉजी विभाग
विभाग और कोऑर्डिनेटरी कार्यालय, भारत सरकार

birac
BIOPHARMACEUTICAL RESEARCH AND INNOVATION MANAGEMENT

nbm
NATIONAL BIODIVERSITY MANAGEMENT

NIH National Institutes of Health
Turning Discovery Into Health

The Department of Bioethics

प्रस्ताव आमंत्रण हैं
इंडो-यूएस क्लिनिकल रिसर्च
एथिक्स फेलोशिप

इंडो-यूएस वैक्सिन एक्शन प्रोग्राम (VAP) के तत्वावधान के लिए प्रस्ताव आमंत्रित हेतु और राष्ट्रीय बायोफार्मा मिशन (बायोटेक्नोलॉजी विभाग और विश्व बैंक द्वारा संयुक्त रूप से वित्त पोषित)

कॉल ओपन: 01 जुलाई 2022
(साम 5:30 बजे IST)
जमा करने की अंतिम तिथि: 29 अगस्त 2022
(साम 5:30 बजे IST)
कॉल एक्सटेंडेंड रू
28 सितंबर 2022, (साम 5:30 बजे IST)

उद्देश्य
बायोटेक्नोलॉजी विभाग, भारत सरकार और डिपार्टमेंट ऑफ बायोएथिक्स, (एनआईएच), अमेरिका द्वारा संयुक्त रूप से नैदानिक अनुसंधान नैतिकता के क्षेत्र में क्षमता बढ़ाने के उद्देश्य से संकलित कार्यक्रम।

फेलोशिप और अनुसंधान अनुदान राशि
जिन उम्मीदवारों पास मेज़बान संस्थान में स्थायी पद है उन उम्मीदवारों के लिए 2.00 लाख / वर्ष रुपये की एक फेलोशिप राशि होगी, अस्थायी / सविदात्मक / तदर्थ पद पर काम करने वाले उम्मीदवारों के लिए अतिरिक्त शोध अनुदान के साथ रुपये 10.20 लाख / वर्ष से अधिक नहीं होनी चाहिये। एनबीएम-बाइरेक द्वारा प्रत्येक चयनित साथी (केवल दो उम्मीदवार) के लिए 3 साल की अवधि के लिए 40 लाख होनी चाहिये। चयनित फेलो एनआईएच के डिपार्टमेंट ऑफ बायोएथिक्स, यूएस में अनुसंधान के उद्देश्य से शॉर्ट फोकस्ड विज़िट के लिए पात्र होगा, जिसे एनआईएच, यूएस द्वारा समर्थित किया जाएगा।

कृपया किसी भी प्रश्न के लिए संपर्क करें: मिशन निदेशक पीएमयू-एनबीएम technical@birac.nic.in, mdpbumgf@birac.nic.in



For further information please contact:
Biotechnology Industry Research Assistance Council (BIRAC)
 1st Floor, MTNL Building, 9, CGO Complex, Lodhi Road, New Delhi-110003, INDIA
 Tel: +91-11-24389600 | F ax: +91-11-24389611
 E-mail: birac.bdt@nic.in | Web: www.birac.nic.in
 Follow us on Twitter : @BIRAC_2012